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Lipopolysaccharides (LPS) are presumed to contribute to the inflammatory response in sepsis. We 
investigated if extracorporeal Alteco® LPS Adsorber for LPS removal in early Gram-negative septic 
shock was feasible and safe. Also, effect on endotoxin level, inflammatory response and organ 
function were assessed.   
Methods 
A pilot, double-blinded, randomized, Phase IIa, feasibility clinical investigation was undertaken in six 
Scandinavian intensive care units aiming to allocate thirty-two septic shock patients with abdominal 
or urogenital focus to LPS Adsorber therapy or a Sham Adsorber, therapy without active LPS-binding. 
The study treatment was initiated within 12 hours of inclusion and given for six hours daily on first 
two days. LPS was measured in all patients. 
Results 
The investigation was terminated after 527 days with eight patients included in the LPS Adsorber 
group and seven in the Sham group. Twenty-one adverse effects, judged not to be related to the 
device, were reported in three patients in the LPS Adsorber group and two in the Sham group. Two 
patients in the Sham group and no patients in the LPS Adsorber group died within 28 days. Plasma 
LPS levels were low without groups differences during or after adsorber therapy. The changes in 
inflammatory markers and organ function were similar in the groups. 
Conclusions 
In a small cohort of patients with presumed Gram-negative septic shock, levels of circulating 
endotoxin were low and no adverse effects within 28 days after LPS adsorber-treatment were 
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Septic shock is a life-threatening condition with profound systemic inflammatory activation triggered 
by infection (1). Despite management with antimicrobial therapy, source control and support of 
failing organs, mortality rates remain high (2). Therefore, the development of new treatment options 
for sepsis and septic shock is crucial for medical, humanitarian and health-economic reasons.  
Gram-negative bacteria are a common cause of septic shock. Lipopolysaccharides (LPS), a group of 
endotoxins, are molecules found in the outer membrane of these bacteria. They are potent 
activators of the inflammatory system through the innate immune system and have been considered 
as one of the key triggers of the systemic inflammatory response (3-5). Hence, reducing the levels of 
LPS seems to be a logical and desirable strategy in the treatment of sepsis and septic shock. It is 
reasonable to hypothesize that using LPS adsorption membranes for the treatment of selected 
patients in the early phase of Gram-negative septic shock, within a strictly defined time-frame after 
the onset of clinical symptoms, may offer therapeutic benefits. Several extracorporeal endotoxin 
removal devices, based on various endotoxin-binding mechanisms, have been investigated with 
diverging results (6-10). 
Case reports from patients with septic shock suggest that endotoxin removal may be achieved in 
clinical practice with an LPS adsorber system (Alteco Medical AB, Lund, Sweden) with a high LPS 
affinity peptide binding mechanism, hereafter referred to as LPS Adsorber (11, 12). However, no 
randomized controlled trial has investigated the potential benefits of this LPS Adsorber.  
We postulated that in patients with Gram-negative infections, early and extensive removal of LPS 
would limit the inflammatory response that characterizes septic shock. Unlike other device trials, the 
LPS Adsorber was compared to an identical Adsorber cartridge without active LPS-binding peptide. 
Thus, a double-blinded randomized sham -controlled pilot feasibility trial was performed.   
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The primary endpoint was characterization of all reported adverse effects reported as Serious 
Adverse Device Effects (SADE) and Adverse Device Effects (ADE) as well as Serious Adverse Effects 
(SAE) and Adverse Effects (AE). Secondary endpoints were: changes in LPS levels during LPS Adsorber 
therapy; changes in the extent of organ failure; intensive care unit (ICU) mortality and 28-day 
mortality, ICU and hospital length-of-stay (LOS). We also measured plasma markers of the innate 
immune system, i.e. cytokines and complement activation as they are regarded as the first-line 





This was a pilot multicenter, stratified, parallel group, double-blinded, randomized, Phase IIa, 
feasibility clinical investigation reported according the CONSORT and the SPIRIT guidelines (13, 14). 
The protocol has been reported previously (15). 
The clinical investigation was conducted in compliance with applicable international standards (ISO 
14155:2011), as well as with the ethical principles of the Declaration of Helsinki as adopted by the 
World Medical Association. The study was approved by local ethical review boards (Uppsala, Sweden; 
2014/370, ALT C1-01; Norway, 2014/1059/REK vest; Tampere, Finland R14130).  
The final protocol (6.0) was amended during the study on the 12th of December, 2016. 
Six general intensive care units (ICU) in Uppsala and Linköping, Sweden, Bergen and Oslo, Norway, 
and Tampere and Kuopio, Finland participated. We aimed at including 32 patients admitted to the 
ICU with confirmed septic shock after informed consent from the patient or legal representative. 
Recruitment of patients started in September 2015. Patients were stratified according to the origin of 
their suspected endotoxemia: 20 septic shock patients with abdominal focus (Stratum A) and 12 
patients with urogenital focus (Stratum B). Patients were randomly allocated to standard care + LPS 
Adsorber therapy (LPS Adsorber group), or standard care + identical adsorber cartridge without 
active LPS-binding peptide (Sham group). 
All inclusion and exclusion criteria are listed in the Supplemental Digital Content (SDC). A concise 
version is listed below. Upon enrolment (i.e. pre-treatment phase), patients admitted to the ICU with 
suspected endotoxemia were screened for fulfilment of the “Illness Severity Criteria” confirming 
early stage severe sepsis. Within six hours of enrolment, patients who fulfilled the “Treatment 
Criteria” confirming septic shock were randomized.  
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Illness Severity Criteria 
1) Patients must have suspected infection of abdominal or urogenital origin for which the patient is 
receiving intravenous antimicrobial therapy 
2) Patients must have systemic inflammatory response syndrome (SIRS)(16) 
3) At least one of the following criteria during the six hours prior to clinical investigation entry: 
a) Metabolic acidosis 
b) Acute oliguria/renal injury 
c) Acute hepatic dysfunction 
d) Thrombocytopenia  
Treatment Criteria 
4) SOFA score of 10 or higher (17), AND a Simplified Acute Physiology Score (SAPS II) of 58 or higher 
(18). 
5) Patients must have received ≥ 30 mL/kg of intravenous fluid within the six hours prior to 
randomization. 
6) Vasopressor support for at least two hours prior to randomization to maintain mean arterial 
pressure (MAP) > 65 mmHg or systolic arterial pressure > 90 mmHg. 
7) The clinical investigation intervention initiated within 12 hours of fulfilment of the illness severity 
criteria. 
Randomization 
Patients were randomized with 1:1 ratio in blocks of four stratified by Stratum to either LPS 
Adsorber, or Sham groups by being treated with a randomly numbered blinded cartridge with the 
lowest serial number on site. Each site received therefore at least four blinded device packages per 
shipment. Study investigators, laboratory and research staff were blinded to treatment allocation 
and data until the analyses for the final report. Stratum A and Stratum B patients were kept apart by 




Figure S1 (SDC) summarizes the timeline of the clinical investigation. Treatment with LPS Adsorber or 
Sham adsorber initiated within six hours (Day 1) following fulfilment of the “Treatment Criteria” and 
given for six hours. Dalteparin or tinzaparin as bolus was used as anticoagulation during each 
treatment session. A second device treatment was performed 24 hours after the end of the first 
device treatment on Day 2. Treatment on Day 2 was not given if septic shock had resolved (e.g. no 
need for vasopressor support, new limitations of care). At least one treatment session with two 
hours of treatment was required to fulfill the treatment protocol. Patients were followed to 28 days 
after enrolment. Apart from the protocol for LPS or Sham adsorber therapy, management of the 
patients was at the discretion of the attend physician.   
Endotoxin analysis 
Endotoxin was analyzed with limulus amebocyte lysate assay (LAL; Pierce LAL Chromogenic 
Endotoxin Quantitation Kit, Thermo Scientific, Waltham, MA) measuring endotoxin activity as well as 
by high-performance liquid chromatography coupled with mass spectrometry (HPLC/MS) quantifying 
esterized 3-hydroxymyristate (3OH), the most abundant hydroxylated fatty acid of the lipid A moiety 
of endotoxin (19). 
Complement activation and Cytokines 
Complement activation was measured by the plasma terminal C5b-9 complement complex (TCC). 
Also, ten cytokines were measured: Interleukin (IL)-6, IL-8, IL-10, interferon gamma-induced protein 
10 (IP-10), monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 1 beta (MIP-
1β), tumor necrosis factor (TNF), IL-1 receptor antagonist (IL-1RA), Regulated on Activation, Normal T 
Cell Expressed and Secreted (RANTES) and eotaxin. See also the SDC. 
Organ failure 
Sequential Organ Failure Assessment (SOFA) score, renal function, liver function, circulatory support 




Data was collected by local research staff. Sites were monitored regularly by the clinical research 
organization (CRO; TFS AB, Lund, Sweden). Training, assessment of collected data, data storage and 
management were performed by the CRO. 
Statistics 
The statistical analysis plan was published prior to commencing the study (15). Since this was a pilot 
study and with no evaluation of primary performance variables, the sample size was chosen for 
practical reasons. The Full Analysis Set consists of all randomized patients who were randomized and 
was analyzed by intention to treat. Differences in parametric data were assessed by t-tests or mixed 
linear models, while nonparametric data were assessed by Mann-Whitney, Wilcoxon paired or 
Friedmans ANOVA tests as appropriate. Correlations were assessed with Spearman-Rank 
correlations. A p<0.05 was considered significant. Statistica® 13.2 software (Statsoft, Tulsa, OK) and 






The study was terminated prior to reaching the pre-specified number of patients due to a low 
inclusion rate after 527 days, when 15 patients had been enrolled, of whom eight randomized to the 
LPS Adsorber and seven to the Sham group. Eight patients completed the full treatment protocol 
with two treatments. The inclusion of patients is depicted in Figure 1. 
Patient characteristics are presented in Table 1. Six of 15 patients had growth of Gram negative 
bacteria in blood. The microbiological cultures are presented in Table S1 (SDC). The most common 
verified source of infection was colon perforation followed by cholangitis in septic shock patients 
with abdominal focus. 
Safety and feasibility 
Including SAEs (SDC, Table S2), there were a total of 21 AEs in five patients (33.3%): 3 patients in the 
LPS Adsorber group and 2 patients in the Sham group. No AEs were judged to be related to device 
treatment i.e. none were SADE or ADE. 
Four patients in the LPS adsorber group and three patients in the Sham group had adsorber devices 
replaced due to clotting. One patient in each group discontinued the clinical investigation because of 
repeated clotting of the device. One patient in the LPS Adsorber group discontinued because a lack of 
need for further ICU care after the first treatment.  
Endotoxin levels in plasma 
Endotoxin (LPS) levels measured with the LAL assay were below the detection limit in almost all 
samples (data not shown). Quantification of endotoxin by measuring 3OH showed very low levels of 
endotoxin and no difference in endotoxin levels between patients treated with LPS and sham 




The complement activation marker, TCC, increased in a biphasic fashion during the time periods 
corresponding to the LPS and sham adsorber treatments without differences between the groups, 
consistent with an equal activation of complement by the two devices (Figure 2). The activation by 
the devices contributed more to the complement activation than the sepsis per se. 
The 10 cytokines showed a marked inter-individual variation with no statistical significance between 
the groups (Figure 2).  They showed distinctly different patterns during the observation period. TNF, 
IL-6, IL-1ra, IL-8 and MIP-1β were increased from start, and gradually declined to baseline levels. 
RANTES showed a similar pattern, except for a peak in the LPS adsorber group at 24 hours. IP-10 
increased markedly from start to 24 hours and then declined. Eotaxin declined after start and then 
showed a patter similar to TCC with two peaks corresponding to the adsorption periods. MCP-1 and 
IL-10 stayed low during the whole observation period.  
Organ function 
The median pre-treatment SOFA score was 12 in both groups prior to randomization, that were 
similar between the groups during the study (Table 2). The extent of organ failure expressed as Urine 
output per day, Cystatin C estimated glomerular filtration rate (eGFRCyst), Plasma bilirubin, 
Vasopressor dependency index, Arterial Lactate levels, PaO2/FiO2 ratio, and Blood platelet count 
during the first two days of the study were also similar between the groups. Although most of these 
variables improved during the first two days, platelets decreased in both groups during this period 
(p<0.05). Renal replacement therapy free days were 23 (12-28) vs. 12 (1-26), vasopressor free days 
24 (20-26) vs. 24 (21-26), and ventilator free days (up to 28 days) were 21 (20-27) vs. 23 (19-25), for 
the LPS Adsorber group vs. Sham group, respectively (p=n.s. for all). 3OH did not correlate to SAPS, 
SOFA score, PaO2/FiO2 ratio, Vasopressor dependency index, Arterial Lactate, Blood platelet count, 




Two patients, one male and one female, died within 28 days in the Sham group (after eight and 10 
days), whereas no patients died in the LPS Adsober group. ICU LOS was 11 (6-14) days in the LPS 
Adsorber group and 11 (7-27) in the Sham group. One from the LPS Adsorber group (24 days) and 
one from the Sham group (22 days) were discharged from hospital before 28-days. 
Discussion 
The aim of this double-blinded randomized pilot study was to investigate the safety, feasibility, and 
potential biological and clinical effects of the specific, high affinity, high capacity LPS Adsorber system 
(11, 12). The investigation was terminated prematurely due to low inclusion rate, with less than half 
of the pre-set number of patients included. LPS Adsorber treatment was safe in this small cohort of 
patients, however technical problems, specifically clotting, was very common leading to abrogated 
adsorber treatments. Plasma endotoxin levels were low both before and after treatment, and were 
not different in the LPS adsorber and the Sham groups. The extent of inflammatory reaction, organ 
dysfunction and outcome were similar in the LPS adsorber and the Sham groups. 
Given that this is a pilot study and the pre-set number of patients was not reached, the conclusions 
from the study are limited. Yet, several findings are of interest for further studies using the LPS 
Adsorber and for studies in other anti-LPS strategies. Importantly, the study shows that double-
blinded device studies are feasible in the critical care setting.  
Patients undergoing LPS adsorber therapy did not experience more adverse effects compared to the 
Sham group.  However, our data suggests that the adsorption procedure induced complement 
activation as measured by TCC, platelet consumption and eotaxin increase in both groups.  
Although LPS levels in plasma have been reported to be increased during the course of sepsis (6), 
both in vitro and clinical data suggests that endotoxin levels are highest in early phase of septic shock 
(20, 21). This study was thus designed assuming that LPS adsorption would be most beneficial 
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immediately after the initial dose of antibiotics was administered.  Yet, we found low LPS levels 
despite inclusion criteria aiming at identifying patients with high endotoxin levels. Endotoxin levels 
were below the detection limit with LAL and low with HPLC/MS method (22). A reason for this could 
be that endotoxin levels decreased after the initial dose of antibiotics prior to LPS adsorber 
treatment similarly to a previous report (21). Alternatively, given the low mortality, despite the 
preset SAPS II and SOFA requirements, the endotoxin levels may have been low due to low degree of 
acute illness. A breakdown of LPS in the samples cannot be excluded. However, blood samples were 
handled according to our standard laboratory procedures, and we have previously reported 
detectable endotoxin levels from experimental research with these methods (23, 24).  
The levels of endotoxin estimated by 3OH were low and did not decrease during LPS Adsorber 
therapy. This raises the question if extracorporeal LPS-adsorber therapies add substantially to 
endogenous endotoxin elimination. Although there are reports that imply decreased endotoxin levels 
with the endotoxin adsorber used in our study (11, 12), experimental and in vitro data have 
challenged all currently used LPS-adsorber therapies  (23, 25).  
Previous large randomized controlled studies on extracorporeal endotoxin elimination (6-10) 
included patient cohorts with variable illness severity. We aimed to include patients with high 
severity of illness with a predicted 28 day mortality over 40% setting high SAPS II and SOFA 
requirements for inclusion (26, 27). However, despite reaching the preset illness severity scores the 
mortality in our study was 13% at 28 days. Both patients who died received sham adsorber treatment 
while no patients died in the LPS Adsorber group. The occurrence of death to the Sham group does 
not yield a statistical difference and given the low number of patients in the study, even if there was 
difference the fragility index of this investigation would be very low (28). 
Another aim of the study was to start LPS removal as early as possible after identifying an eligible 
patient. We experienced substantial difficulties in finding patients with a relatively specific group of 
pathologies. Specifically, capturing patients not responding to initial resuscitation (thus presumed to 
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have high mortality), obtaining informed consent in these patients, then initializing a complex 
therapy within a short timeframe were logistical challenges. This problem is underlined by the 
decrease of most inflammatory mediators in our study irrespective of LPS Adsorber or sham 
treatment was given, suggesting that any intervention aimed at removing endotoxin or inflammatory 
mediators would need to be instituted very early during the course of septic shock, preferably with 
first dose of antibiotics. Alternatively, endotoxin removal therapies should be directed at a group 
with already high pre-treatment endotoxin levels, that we were unable to identify using clinical 
criteria alone.  
Strengths and Limitations 
Unlike previous studies (6-10), as far as we know, this is the first double-blinded extracorporeal 
endotoxin elimination study, which was made possible with a sham cartridge without LPS adsorber 
properties. Other obvious strengths of the study are the extensive clinical and laboratory data 
collected, including the analysis of inflammatory markers as well as the follow-up to 28 days.  
On the other hand, early termination significantly limits the power of this study. However, one aim of 
this pilot study was to test the protocol for a possible phase IIb trial. With the current inclusion rate 
in six large centers several additional years would have been required to finalize the study. Another 
limitation of the study was that only one patient with urogenital sepsis was included. Urogenital 
sepsis is caused in the majority of cases by Gram-negative bacteria (29). Although septic shock is not 
uncommon in this group of patients, illness severity scores in this group were below inclusion levels. 
A further consequence of the early termination is that the characteristics of the patients at inclusion 
differed in some aspects, limiting the validity of findings that are based on group differences.  
The study was designed to identify patients with Gram-negative sepsis, but not all patients presented 
with these bacteria according to culture results. Although the aim of the study was to decrease high 
levels of endotoxin in the blood related to Gram-negative infection, endotoxemia is present in sepsis 
17 
 
of other etiologies too (30), suggesting that LPS adsorption therapy could have been of benefit even 
in patients with other types of severe infections.  
Future studies 
Based on this and other studies the role of endotoxin removal in sepsis is uncertain (10, 13). Any 
future study must identify patients with high endotoxin levels. Moreover the endotoxin removal 
should be started early with high capacity and specific endotoxin adsorbers. 
Conclusions 
In a small cohort of patients with presumed Gram-negative sepsis, no adverse effects of LPS 
adsorber-treatment were observed within 28 days after treatment, but it did not offer any clinical 
benefit compared to a sham device. The low level of circulating endotoxin suggests that anti-
endotoxin strategies are unlikely to give the desired benefit in this selected group of patients.   
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List of abbreviations 
AE Adverse effects 
ALT Alanine aminotransferase 
AST Aspartate aminotransferase 
CIP Clinical investigation plan 
CRO Clinical research organization 
CRRT Continuous renal replacement therapy 
CT Computed tomography 
eCRF Electronic case report form 
eGFRCyst Estimated glomerular filtration rate based on Plasma Cystatin C 
HIT II Heparin-induced thrombocytopenia II 
HPLC-MS High-performance liquid chromatography coupled with mass spectrometry  
ICU Intensive care unit 
IMD Interventional medical device 
LAL Limulus amebocyte lysate assay 
LOS Length-of-stay 
MAP Mean arterial pressure 
PaO2/FiO2 Arterial oxygen tension/Fraction of inspired oxygen 
RRT Renal replacement therapy 
SAE Serious adverse effects 
SAPS II Simplified acute physiology score 
SIRS Systemic inflammatory response syndrome 
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Figure 1. CONSORT diagram 
Figure 2. LPS levels, complement activation (TCC) and 10 cytokines during LPS Adsorber and sham 
treatment of septic patients. Red lines represent LPS adsorber group, green lines represent Sham 
adsorber group. All values are displayed as median (line in the box), mean (dot) and interquartile 
range (box) and 10-90th percentile (whiskers). No group differences were seen. Abbreviation of 
cytokines are as described in Materials and Methods.   
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